These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16583786)

  • 1. Effects of the ritonavir price increase on the cost of protease inhibitor regimens in United States.
    Lee WC; Williams KW; Chen E; Liu LZ; Pashos CL
    Manag Care Interface; 2006 Mar; 19(3):27-32. PubMed ID: 16583786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abbott Laboratories increases Norvir price fivefold.
    James JS
    AIDS Treat News; 2003 Dec; (397):3-5. PubMed ID: 14989182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Backlash over ritonavir price hike.
    Huff B
    BETA; 2004; 16(4):15-7. PubMed ID: 15386839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controversy over ritonavir price increase.
    AIDS Clin Care; 2004 Feb; 16(2):15. PubMed ID: 15032179
    [No Abstract]   [Full Text] [Related]  

  • 5. Norvir hangover.
    Clifton CE
    Posit Aware; 2004; 15(2):7-9. PubMed ID: 15106524
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
    Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
    J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Call to rescind price boosting of ritonavir.
    Quirk M
    Lancet Infect Dis; 2004 Feb; 4(2):68. PubMed ID: 14959760
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.
    Bierman WF; van Agtmael MA; Nijhuis M; Danner SA; Boucher CA
    AIDS; 2009 Jan; 23(3):279-91. PubMed ID: 19114854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
    Youle M
    J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosamprenavir calcium plus ritonavir for HIV infection.
    Torres HA; Arduino RC
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):349-63. PubMed ID: 17547501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection.
    Sahali S; Chaix ML; Delfraissy JF; Ghosn J
    AIDS Rev; 2008; 10(1):4-14. PubMed ID: 18385776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients.
    Sension M; Piliero PJ
    J Assoc Nurses AIDS Care; 2007; 18(1):36-47. PubMed ID: 17338984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug pricing. AHF presses for indemnification over Norvir price increase.
    AIDS Policy Law; 2004 Feb; 19(4):2. PubMed ID: 15045980
    [No Abstract]   [Full Text] [Related]  

  • 19. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.
    Fox ZV; Geretti AM; Kjaer J; Dragsted UB; Phillips AN; Gerstoft J; Staszewski S; Clotet B; von Wyl V; Lundgren JD
    AIDS; 2007 Oct; 21(15):2033-42. PubMed ID: 17885293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.